Catalyst
Slingshot members are tracking this event:
The full dataset from the Phase 2 proof-of-concept trial of Argenix's(ARGX) efgartigimod in pemphigus vulgaris (PV) is expected in the first half of 2019
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ARGX | Community voting in process | |||||
Additional Information
Interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris released.
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 13, 2020
Occurred Source:
https://www.argenx.com/sites/default/files/event-attachment/SID_Presentation_Abstract_537_Goebeler_050820_Final_01_0.pdf
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Pemphigus Vulgaris, Efgartigimod
